Literature DB >> 23559196

West nile virus infection and myasthenia gravis.

A Arturo Leis1, Gabriella Szatmary, Mark A Ross, Dobrivoje S Stokic.   

Abstract

INTRODUCTION: Viruses are commonly cited as triggers for autoimmune disease. It is unclear if West Nile virus (WNV) initiates autoimmunity.
METHODS: We describe 6 cases of myasthenia gravis (MG) that developed several months after WNV infection. All patients had serologically confirmed WNV neuroinvasive disease. None had evidence of MG before WNV.
RESULTS: All patients had stable neurological deficits when they developed new symptoms of MG 3 to 7 months after WNV infection. However, residual deficits from WNV confounded or delayed MG diagnosis. All patients had elevated acetylcholine receptor (AChR) antibodies, and 1 had thymoma. Treatment varied, but 4 patients required acetylcholinesterase inhibitors, multiple immunosuppressive drugs, and intravenous immune globulin or plasmapheresis for recurrent MG crises.
CONCLUSIONS: The pathogenic mechanism of MG following WNV remains uncertain. We hypothesize that WNV-triggered autoimmunity breaks immunological self-tolerance to initiate MG, possibly through molecular mimicry between virus antigens and AChR subunits or other autoimmune mechanisms.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  West Nile virus; autoimmunity; molecular mimicry; myasthenia gravis; neuromuscular junction; poliomyelitis

Mesh:

Substances:

Year:  2013        PMID: 23559196     DOI: 10.1002/mus.23869

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  22 in total

Review 1.  Myasthenia gravis and infectious disease.

Authors:  Nils Erik Gilhus; Fredrik Romi; Yu Hong; Geir Olve Skeie
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

Review 2.  Current developments in understanding of West Nile virus central nervous system disease.

Authors:  Kenneth L Tyler
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

Review 3.  Virus infection, antiviral immunity, and autoimmunity.

Authors:  Daniel R Getts; Emily M L Chastain; Rachael L Terry; Stephen D Miller
Journal:  Immunol Rev       Date:  2013-09       Impact factor: 12.988

Review 4.  Immunotherapy in myasthenia gravis in the era of biologics.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

5.  A Systematic Review of the Potential Implication of Infectious Agents in Myasthenia Gravis.

Authors:  Victoria Leopardi; Yu-Mei Chang; Andrew Pham; Jie Luo; Oliver A Garden
Journal:  Front Neurol       Date:  2021-06-14       Impact factor: 4.003

6.  Seropositivity for West Nile Virus Antibodies in Patients Affected by Myasthenia Gravis.

Authors:  Marilena Greco; Pietro Cofano; Giambattista Lobreglio
Journal:  J Clin Med Res       Date:  2016-01-26

7.  Viral Impact in Autoimmune Diseases: Expanding the "X Chromosome-Nucleolus Nexus" Hypothesis.

Authors:  Wesley H Brooks
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

8.  Severe Myasthenic Manifestation of Leptospirosis Associated with New Sequence Type of Leptospira interrogans.

Authors:  Matthias Tomschik; Inga Koneczny; Anna-Margarita Schötta; Sebastian Scharer; Merima Smajlhodzic; Paloma Fernandes Rosenegger; Martin Blüthner; Romana Höftberger; Fritz Zimprich; Gerold Stanek; Mateusz Markowicz
Journal:  Emerg Infect Dis       Date:  2019-05       Impact factor: 6.883

Review 9.  Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms.

Authors:  Maria K Smatti; Farhan S Cyprian; Gheyath K Nasrallah; Asmaa A Al Thani; Ruba O Almishal; Hadi M Yassine
Journal:  Viruses       Date:  2019-08-19       Impact factor: 5.048

10.  Metagenome-wide association study of gut microbiome revealed potential microbial marker set for diagnosis of pediatric myasthenia gravis.

Authors:  Peng Liu; Yiqi Jiang; Shanshan Gu; Yinping Xue; Hongxia Yang; Yongzhao Li; Yaxuan Wang; Congya Yan; Pei Jia; Xiaoting Lin; Guoyan Qi
Journal:  BMC Med       Date:  2021-07-08       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.